Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T20:51:37.420Z.
Consensus retrieved: 2026-10-06T11:50:20.347Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T20:51:37.420Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8e2f3ec51e074b036058196f7f903a3cac1545bb57f25a27b7ce4fd0c255fbf9
Forward PE Ratio (N/A) = Dated Quote Price ($3.76) / Consensus Forward EPS ($-0.30)
FORWARD PE RATIO
N/A
Galectin Therapeutics Inc.
Market Cap
$247.62M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Galectin Therapeutics Inc. (GALT) | $247.62M | N/A |
| Sol-Gel Technologies Ltd. (SLGL)vs › | $247.27M | N/A |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $248.50M | N/A |
| Upstream Bio, Inc. (UPB)vs › | $249.79M | N/A |
| Lifecore Biomedical, Inc. (LFCR)vs › | $241.94M | N/A |
| Q32 Bio Inc. (QTTB)vs › | $241.39M | N/A |
| Quantum-Si incorporated (QSI)vs › | $241.34M | N/A |
| Anika Therapeutics, Inc. (ANIK)vs › | $255.88M | 18.21 |
| Century Therapeutics, Inc. (IPSC)vs › | $239.02M | N/A |
| High Tide Inc. (HITI)vs › | $239.01M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $3.76, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.30 | $-0.30 – $-0.30 | 1 | n/m |
| 2027-12-31 | $-0.23 | $-0.23 – $-0.23 | 1 | n/m |
| 2028-12-31 | $-1.06 | $-1.06 – $-1.06 | 1 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
